AngioDynamics Inc (ANGO)

AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. The company operates through Med Tech and Med Device segments. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers' off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which include angiographic catheters, guidewires, drainage catheters, and micropuncture kits for use in invasive procedures. In addition, the company provides total abscession drainage catheters for multi-purpose/general and biliary configurations, and nephrostomy options; mini stick MAX Coaxial microintroducer kits and micro-introducer kits; ports; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.

Ticker
ANGO
Exchange
Nasdaq
Sector
Healthcare
Industry
Medical Instruments & Supplies
Market cap
$497.64M
52-week range
$9.39 - $16.29

Valuation

Share price
$11.73 (close of Nov 6, 2026)
P/E (TTM)
-14.85x
Price to book
3.04x
Price to free cash flow
344.63x
Enterprise value
$470.92M
Book value per share
$3.86

Price performance

PeriodChange
1 day-0.68%
5 days-2.17%
1 month-18.65%
3 months-22.37%
6 months+6.15%
Year to date-8.64%
1 year0.00%
3 years+74.55%
5 years-62.12%
10 years-25.99%
All time-13.75%

Short interest

As of
Oct 15, 2026
Short % of float
4.92%
Shares short
1.92M
Days to cover
1.46
Change since prior report
+48.05%
Source
FINRA consolidated short interest

Profitability and growth

Return on equity
-21.51%
Return on invested capital
-21.96%
Return on assets
-13.75%
Return on capital employed
-20.75%
Gross margin
54.62%
Net margin
-11.48%
EBITDA margin
-5.30%
Revenue growth
9.46%

Cash flow and balance sheet

Free cash flow yield (TTM)
0.29%
Current ratio
2.40x
Net debt to EBITDA
-30.93x

Latest reported year

Period end
May 31, 2026
Fiscal year
2026
Revenue
$320.17M
Cost of revenue
$145.28M
Gross profit
$174.89M
EBITDA
-$16.97M
Net income
-$36.74M
Earnings per share
$-0.88
Research and development
$29.45M
Interest expense
$299.00K
Shares outstanding
41.53M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2026-05-31$320.17M$174.89M-$36.74M-$0.88
2025-05-31$292.50M$157.71M-$33.99M-$0.83
2024-05-31$303.91M$154.70M-$184.35M-$4.59
2023-05-31$338.75M$174.25M-$52.44M-$1.33
2022-05-31$316.22M$165.73M-$26.55M-$0.68
2021-05-31$291.01M$156.79M-$31.55M-$0.82
2020-05-31$264.16M$150.27M-$166.79M-$4.39
2019-05-31$270.63M$156.00M$61.34M$1.64
2018-05-31$261.65M$143.86M$16.34M$0.44
2017-05-31$269.79M$143.95M$5.01M$0.14

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2026-05-3154.62%-11.48%-21.51%-21.96%
2025-05-3153.92%-11.62%-18.58%-20.67%
2024-05-3150.90%-60.66%-89.67%-88.03%
2023-05-3151.44%-15.48%-13.86%-11.11%
2022-05-3152.41%-8.40%-6.25%-5.47%
2021-05-3153.88%-10.84%-7.18%-6.85%
2020-05-3156.89%-63.14%-36.67%-35.62%
2019-05-3157.64%22.67%9.98%-0.78%
2018-05-3154.98%6.24%3.01%-1.12%
2017-05-3153.36%1.86%0.97%-0.91%

Cash and debt by year

Period endCashDebt
2026-05-31$53.86M-
2025-05-31$55.89M-
2024-05-31$76.06M-
2023-05-31$44.62M$49.82M
2022-05-31$28.82M$25.00M
2021-05-31$48.16M-
2020-05-31$54.44M-
2019-05-31$227.64M$124.41M
2018-05-31$74.10M$86.62M
2017-05-31$47.54M$91.32M

Free cash flow by year

Period endFree cash flowStock-based compensation
2026-05-31$508.00K$13.96M
2025-05-31-$14.59M$9.77M
2024-05-31-$30.68M$10.53M
2023-05-31-$3.73M$11.16M
2022-05-31-$11.49M$10.69M
2021-05-31$18.91M$8.63M
2020-05-31-$21.79M$7.59M
2019-05-31$34.32M$9.25M
2018-05-31$38.90M$7.91M
2017-05-31$52.74M$6.18M

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-10-08Aug 2026-$0.10
2026-07-14May 2026-$0.11
2026-04-02Feb 2026-$0.11
2026-01-06Nov 2025-$0.10
2025-10-02Aug 2025-$0.14
2025-07-15May 2025-$0.13
2025-04-02Feb 2025-$0.13
2025-01-08Nov 2024-$0.11

Filings and sources

Company website
angiodynamics.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Intuitive Surgical Inc (ISRG) · Becton Dickinson & Co (BDX) · Medline Inc. (MDLN) · ResMed Inc (RMD) · Alcon Inc (ALC) · West Pharmaceutical Services Inc (WST) · Solventum Corp (SOLV) · Baxter International Inc (BAX)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades